Cargando…

Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?

PURPOSE: Postmastectomy radiation therapy (PMRT) in T1–T2 tumors with 1–3 positive axillary lymph nodes (ALNs) is controversial. This study was to identify prognostic factors of locoregional control (LRC) following mastectomy with or without PMRT for patients with T1-2N1 breast cancer and to discuss...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaofang, Zhang, Li, Zhang, Xiaomeng, Luo, Jurui, Wang, Xuanyi, Chen, Xingxing, Yang, Zhaozhi, Mei, Xin, Yu, Xiaoli, Zhang, Zhen, Guo, Xiaomao, Shao, Zhimin, Ma, Jinli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558198/
https://www.ncbi.nlm.nih.gov/pubmed/34490502
http://dx.doi.org/10.1007/s10549-021-06378-2
_version_ 1784592502819389440
author Wang, Xiaofang
Zhang, Li
Zhang, Xiaomeng
Luo, Jurui
Wang, Xuanyi
Chen, Xingxing
Yang, Zhaozhi
Mei, Xin
Yu, Xiaoli
Zhang, Zhen
Guo, Xiaomao
Shao, Zhimin
Ma, Jinli
author_facet Wang, Xiaofang
Zhang, Li
Zhang, Xiaomeng
Luo, Jurui
Wang, Xuanyi
Chen, Xingxing
Yang, Zhaozhi
Mei, Xin
Yu, Xiaoli
Zhang, Zhen
Guo, Xiaomao
Shao, Zhimin
Ma, Jinli
author_sort Wang, Xiaofang
collection PubMed
description PURPOSE: Postmastectomy radiation therapy (PMRT) in T1–T2 tumors with 1–3 positive axillary lymph nodes (ALNs) is controversial. This study was to identify prognostic factors of locoregional control (LRC) following mastectomy with or without PMRT for patients with T1-2N1 breast cancer and to discuss the selection of patients who might omit PMRT. MATERIALS AND METHODS: Between January 2006 and December 2012, the data of 1474 postmastectomy patients staged pT1-2N1 were analyzed. PMRT was applied in 663 patients. LRC and disease-free survival (DFS) were calculated using the Kaplan–Meier method. Cox regression model was applied in the univariate and multivariate analyses to recognize the recurrence risk factors. RESULTS: With the median follow-up duration of 93 months (range, 5–168 months), 78 patients (5.3%) failed to secure LRC and 220 patients (14.9%) experienced any recurrence. The 7.7-year LRC and DFS was 94.9% and 85.4% respectively in the entire cohort. PMRT significantly improved 7.7-year LRC from 93.4% to 96.6% (p = 0.005), but not the DFS (p = 0.335). Multivariate analysis revealed that PMRT was an independent prognostic factor of LRC (p < 0.001), meanwhile, age ≤ 40 years (p = 0.012), histological grade 3 (p = 0.004), 2–3 positive nodes (p < 0.001) and tumor size of 3–5 cm (p = 0.045) were significantly associated with decreased LRC. The 7.7-year LRC for patients with 0, 1, and 2–4 risk factors was 97.7% / 98.9% (p = 0.233), 95.3% / 98.0% (p = 0.092), and 80.3% / 94.8% (p < 0.001) in the non-PMRT and PMRT group, respectively. CONCLUSIONS: In patients with T1-2N1 breast cancer, clinical-pathological factors including young age, histological grade 3, 2–3 positive nodes, and tumor size of 3–5 cm were identified to be predictors of a poorer LRC following mastectomy. Patients with 0–1 risk factor might consider the omission of PMRT.
format Online
Article
Text
id pubmed-8558198
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-85581982021-11-15 Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy? Wang, Xiaofang Zhang, Li Zhang, Xiaomeng Luo, Jurui Wang, Xuanyi Chen, Xingxing Yang, Zhaozhi Mei, Xin Yu, Xiaoli Zhang, Zhen Guo, Xiaomao Shao, Zhimin Ma, Jinli Breast Cancer Res Treat Clinical Trial PURPOSE: Postmastectomy radiation therapy (PMRT) in T1–T2 tumors with 1–3 positive axillary lymph nodes (ALNs) is controversial. This study was to identify prognostic factors of locoregional control (LRC) following mastectomy with or without PMRT for patients with T1-2N1 breast cancer and to discuss the selection of patients who might omit PMRT. MATERIALS AND METHODS: Between January 2006 and December 2012, the data of 1474 postmastectomy patients staged pT1-2N1 were analyzed. PMRT was applied in 663 patients. LRC and disease-free survival (DFS) were calculated using the Kaplan–Meier method. Cox regression model was applied in the univariate and multivariate analyses to recognize the recurrence risk factors. RESULTS: With the median follow-up duration of 93 months (range, 5–168 months), 78 patients (5.3%) failed to secure LRC and 220 patients (14.9%) experienced any recurrence. The 7.7-year LRC and DFS was 94.9% and 85.4% respectively in the entire cohort. PMRT significantly improved 7.7-year LRC from 93.4% to 96.6% (p = 0.005), but not the DFS (p = 0.335). Multivariate analysis revealed that PMRT was an independent prognostic factor of LRC (p < 0.001), meanwhile, age ≤ 40 years (p = 0.012), histological grade 3 (p = 0.004), 2–3 positive nodes (p < 0.001) and tumor size of 3–5 cm (p = 0.045) were significantly associated with decreased LRC. The 7.7-year LRC for patients with 0, 1, and 2–4 risk factors was 97.7% / 98.9% (p = 0.233), 95.3% / 98.0% (p = 0.092), and 80.3% / 94.8% (p < 0.001) in the non-PMRT and PMRT group, respectively. CONCLUSIONS: In patients with T1-2N1 breast cancer, clinical-pathological factors including young age, histological grade 3, 2–3 positive nodes, and tumor size of 3–5 cm were identified to be predictors of a poorer LRC following mastectomy. Patients with 0–1 risk factor might consider the omission of PMRT. Springer US 2021-09-06 2021 /pmc/articles/PMC8558198/ /pubmed/34490502 http://dx.doi.org/10.1007/s10549-021-06378-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Clinical Trial
Wang, Xiaofang
Zhang, Li
Zhang, Xiaomeng
Luo, Jurui
Wang, Xuanyi
Chen, Xingxing
Yang, Zhaozhi
Mei, Xin
Yu, Xiaoli
Zhang, Zhen
Guo, Xiaomao
Shao, Zhimin
Ma, Jinli
Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
title Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
title_full Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
title_fullStr Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
title_full_unstemmed Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
title_short Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?
title_sort impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with t1-2n1 breast cancer: who can omit adjuvant radiotherapy?
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558198/
https://www.ncbi.nlm.nih.gov/pubmed/34490502
http://dx.doi.org/10.1007/s10549-021-06378-2
work_keys_str_mv AT wangxiaofang impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT zhangli impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT zhangxiaomeng impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT luojurui impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT wangxuanyi impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT chenxingxing impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT yangzhaozhi impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT meixin impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT yuxiaoli impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT zhangzhen impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT guoxiaomao impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT shaozhimin impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy
AT majinli impactofclinicalpathologicalfactorsonlocoregionalrecurrenceinmastectomypatientswitht12n1breastcancerwhocanomitadjuvantradiotherapy